52 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2037. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Mar 2037

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039 2040 2041 2042 204320442045

notable patents all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Multipart Reagents Having Increased Avidity for Polymerase Binding US 10,982,280

Cited by 41 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.

Ends Mar 2039 · High confidence Also notable

High Performance Fluorescence Imaging Module for Genomic Testing Assay US 11,459,608

Cited by 37 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2041.

Ends Jan 2041 · Medium confidence Also notable

Multivalent Binding Composition for Nucleic Acid Analysis US 11,287,422

Cited by 35 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.

Ends no later than Sep 2040 · Low confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

3 fees due Apr 10 to 24, 2027 · next Apr 10
1 fee due Jul 2, 2027
The maintenance fee for Compositions and Methods for Pairwise Sequencing (US 11,859,241) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
2 fees due Aug 6 to 27, 2027 · next Aug 6

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

What they patent

The 5 largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Multivalent Binding Composition for Nucleic Acid Analysis	8 in force	to Oct 2042
Single-Pass Primary Analysis	7 in force	to Apr 2042
High Performance Fluorescence Imaging Module for Genomic Testing Assay	4 in force	to Jan 2041
Compositions and Methods for Pairwise Sequencing	3 in force	to Jul 2041
Engineered Polymerases with Reduced Sequence-Specific Errors	2 in force	to Jan 2043

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 10,233,490	Methods for Assembling and Reading Nucleic Acid Sequences from Mixed Populations In force Term ends Mar 9, 2037 · High confidence	In force	Term ends Mar 9, 2037	High confidence
US 10,704,094	Multipart Reagents Having Increased Avidity for Polymerase Binding In force Term ends Mar 25, 2039 · High confidence	In force	Term ends Mar 25, 2039	High confidence
US 10,876,148	De Novo Surface Preparation and Uses Thereof In force Term ends Mar 25, 2039 · High confidence	In force	Term ends Mar 25, 2039	High confidence
US 10,982,280	Multipart Reagents Having Increased Avidity for Polymerase Binding In force Term ends Mar 25, 2039 · High confidence	In force	Term ends Mar 25, 2039	High confidence
US 12,313,627	Multivalent Binding Composition for Nucleic Acid Analysis In force Term ends Aug 16, 2039 · High confidence	In force	Term ends Aug 16, 2039	High confidence
US 10,768,173	Multivalent Binding Composition for Nucleic Acid Analysis In force Term ends Sep 23, 2039 · High confidence	In force	Term ends Sep 23, 2039	High confidence
US 12,134,766	Methods for Generating Circular Nucleic Acid Molecules In force Term ends Nov 15, 2039 · High confidence	In force	Term ends Nov 15, 2039	High confidence
US 11,426,732	Flow Cell Device and Use Thereof In force Term ends Dec 6, 2039 · Medium confidence	In force	Term ends Dec 6, 2039	Medium confidence
US 11,053,540	High Performance Fluorescence Imaging Module for Genomic Testing Assay In force Ends no later than Sep 9, 2040 · Medium confidence	In force	Ends no later than Sep 9, 2040	Medium confidence
US 11,060,138	Nucleic Acid Sequencing Systems In force Term ends Sep 9, 2040 · High confidence	In force	Term ends Sep 9, 2040	High confidence

10 of 52 patents shown.

Pro members see all 52.

Pro members: see all 52 patents

Also on record, not counted in the 52: 61 applications pending · 49 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Element Biosciences, Inc.